Starpharma (ASX:SPL) Gains Momentum as Investors Track Clinical Preparation and Partnerships

Aditi Sarkar

20 August 2026 08:24 PM AEST

Starpharma (ASX:SPL) Gains Momentum as Investors Track Clinical Preparation and Partnerships

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Starpharma (ASX:SPL) closed at AUD 0.76, up 4.83% on 20 August 2026.
The company develops dendrimer-based pharmaceutical technologies targeting oncology and other healthcare applications.
Q4 FY26 update highlighted DEP HER2-Lu clinical preparation, Partnership milestones and cash balance of AUD 11.0 million.
Investors continue to monitor clinical progress, licensing opportunities, intellectual property development and commercial partnerships.

Starpharma Holdings (ASX:SPL) shares closed at AUD 0.76, up 4.83% on 20 August 2026. The movement reflects a positive Trading session as investors continue to assess the company’s dendrimer technology platform, oncology pipeline and partnership strategy.

Daily share price movements can reflect changes in investor sentiment, trading activity, valuation expectations and broader market conditions. However, a single-session movement does not necessarily indicate a change in the company’s underlying fundamentals, financial position or long-term operating outlook.

Starpharma is a biotechnology company developing dendrimer-based pharmaceutical technologies. The company’s DEP platform is being applied across targeted oncology, radiopharmaceutical and drug delivery opportunities, alongside commercial products including Viraleze and VivaGel BV.

The broader Australian market closed higher on the day. The S&P/ASX 200 (ASX:XJO) closed at 9,083.80 points, up 0.33% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,019.90 points, up 0.37% today.

Within the healthcare sector, the S&P/ASX 200 Health Care (ASX:XHJ) closed at 32,044.30 points, up 1.39% today.

Dendrimer-based healthcare platform

Starpharma operates within the biotechnology sector, focusing on dendrimer technology applications across drug delivery and therapeutic development.

The company’s DEP technology platform uses dendrimers, which are nanoscale molecules designed to improve delivery characteristics of therapeutic agents. Starpharma is applying this platform across oncology programs, including DEP HER2-Lu, a radiopharmaceutical candidate targeting HER2-expressing cancers.

Investors generally assess biotechnology companies through clinical development progress, regulatory milestones, intellectual property strength, partnership activity, funding capacity and potential commercial pathways.

Starpharma’s strategy has increasingly focused on higher-value oncology applications, while maintaining commercial activities through products such as Viraleze and VivaGel BV.

The biotechnology sector is influenced by clinical outcomes, regulatory requirements, research timelines and the ability to secure strategic partnerships that support future development.

Pipeline progress and partnership update

Starpharma’s Q4 FY26 update highlighted continued progress across its DEP platform, including completion of the preclinical data package for DEP HER2-Lu and preparation for a first-in-human Phase 1 clinical study targeted for H2 CY2026. The company completed Good Manufacturing Practice (GMP) dendrimer manufacture to support clinical preparation.

During the quarter, Starpharma filed a new Patent application covering DEP technology in radioligand therapy (RLT), strengthening its intellectual property position in radiopharmaceutical applications.

The company also achieved a milestone under its Research and Option Agreement with Radiopharm Theranostics, triggering a USD 0.5 million option fee and commencing the option period for an exclusive licence opportunity.

Starpharma continued Business development activities through its Star Navigator program, focusing on potential partnerships and opportunities involving its DEP technology. The company also highlighted continued commercial activity from Viraleze and VivaGel BV.

Financially, Starpharma ended FY26 with cash and cash equivalents of AUD 11.0 million as at 30 June 2026. FY26 customer receipts increased 149% compared with FY25 to AUD 12.3 million, supported by an AUD 8.5 million upfront payment received from Genentech in October 2025. Net operating cash outflows reduced to AUD 3.2 million compared with AUD 6.8 million in FY25.

The company continues to focus on advancing DEP HER2-Lu towards clinical development, progressing partnerships and identifying additional applications for its dendrimer platform.

Factors investors generally monitor

Starpharma’s performance is influenced by clinical development progress, partnership outcomes, regulatory pathways and funding capacity.

Clinical milestones remain a key consideration for biotechnology companies. Investors monitor trial commencement, safety data, efficacy results and regulatory interactions as programs move through development stages.

Partnership activity is another important factor. Strategic collaborations can provide funding support, validation and commercial pathways, although investors assess the terms, milestones and execution requirements.

Intellectual property development is also relevant. Patent protection and technology differentiation can influence the long-term potential of biotechnology platforms.

Cash management remains a major consideration because clinical-stage companies require funding to support research, manufacturing, regulatory activities and clinical trials.

Commercial product performance also contributes to Starpharma’s operations. Investors monitor sales trends from Viraleze and VivaGel BV while assessing the company’s transition towards higher-value oncology opportunities.

Understanding the share price movement

Starpharma’s 4.83% share price increase on 20 August 2026 may reflect changes in investor sentiment, trading activity or positioning within the healthcare sector. However, daily share price movements alone do not necessarily represent changes in the company’s underlying fundamentals.

Biotechnology stocks can experience short-term Volatility as investors reassess clinical timelines, partnership developments and future commercial opportunities.

For Starpharma, investors are likely to continue monitoring DEP HER2-Lu progress, radiopharmaceutical partnerships, intellectual property developments and the company’s ability to advance its biotechnology platform.

Conclusion

Starpharma (ASX:SPL) closed at AUD 0.76, up 4.83% on 20 August 2026. The company continues to develop its dendrimer technology platform with a growing focus on targeted oncology applications and strategic partnerships.

While the daily share price movement reflects market activity, investors generally assess Starpharma through broader factors including clinical progress, partnership execution, intellectual property development, Cash Management and commercial opportunities. Recent updates highlighted progress towards DEP HER2-Lu clinical development, radiopharmaceutical opportunities and continued focus on expanding the DEP platform.

FAQs

Q: What was Starpharma’s share price movement on 20 August 2026?

A: Starpharma (ASX:SPL) closed at AUD 0.76, up 4.83% on 20 August 2026.

Q: What does Starpharma do?

A: Starpharma develops dendrimer-based pharmaceutical technologies across oncology, drug delivery and healthcare applications.

Q: What is DEP HER2-Lu?

A: DEP HER2-Lu is Starpharma’s targeted radiopharmaceutical program being developed for HER2-expressing cancers.

Q: What was Starpharma’s latest cash position?

A: Starpharma reported cash and cash equivalents of AUD 11.0 million as at 30 June 2026.

Q: What factors influence Starpharma’s outlook?

A: Investors generally monitor clinical development, regulatory progress, partnerships, intellectual property, funding capacity and commercialisation opportunities.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.